CPT code 90399 designates the administration of an immune globulin product when no more specific CPT code applies. Used nationally across outpatient clinics, infusion centers, and hospital outpatient departments, this unlisted immune globulin administration code ensures providers can report and bill for clinically necessary immune globulin services that lack a distinct code. It matters because immune globulin therapies are commonly used for immunodeficiency, autoimmune, and inflammatory conditions, and the absence of a product-specific code requires consistent documentation to support medical necessity and billing.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding context, common billing considerations, and what to expect when using an unlisted immune globulin administration code. The publication addresses benchmark and policy-related themes: coding rationale for unlisted immune globulin administration, payer coverage considerations, documentation expectations, and typical sites of service where the code is used. Where specific payer policy details are not provided in the input, this summary notes their inclusion in the broader analysis where available.

This piece is intended for a national audience of billing professionals, clinicians involved in infusion therapy, and policy analysts seeking concise guidance on when to report CPT code 90399 and what aspects of billing and documentation are most relevant.